biomedical development News
-
Berkshire Biomedical, Developers of COPA, Recognizes National Prescription Drug Take Back Day
Berkshire Biomedical Corporation (“Berkshire” or “the Company”), focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness, today announced its support and recognition of the DEA’s National Prescription Drug Take Back Day on April 30, 2022. As stated in the DEA’s release, the drug overdose ...
-
Berkshire Biomedical, Developers of COPA, Featured as a 2022 Top Texas Tech Startup in StartupCity Magazine
Berkshire Biomedical Corporation (“Berkshire” or “the Company”) is focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness. The Company announced today that its lead product, the Computerized Oral Prescription Administration System (COPA™), has been honored as a 2022 Top Texas Tech Startup in the ...
-
Showcase
ARAI-2PAM Barda Procurement Award
Broomfield, Colorado, 10/3/2022. Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under this contract (number 75A50122C00082), awarded under the 2004 Project ...
-
Luminostics awarded NIH RADx contract for rapid COVID-19 test
Luminostics has been awarded a contract by the National Institutes of Health (in collaboration with the Biomedical Advanced Research and Development Authority) under the Rapid Acceleration of Diagnostics Tech (RADx Tech) fast track program, which supports the development and commercialization of innovative technologies to significantly increase the U.S. testing capacity for SARS-CoV-2, the virus ...
By Clip Health
-
Antimicrobial Resistance Diagnostic Challenge Semifinalist
Affinity Biosensors Ultra-Rapid Phenotypical AST by Microbe Mass Measurement has been selected as a Step 1 semifinalist in the Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test Challenge by the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR). The ...
-
Aesther Healthcare (AEHA) Announces $75M Share Purchase Agreement for Ocean Biomedical Deal
Aesther Healthcare (NASDAQ:AEHA) announced this morning that it has inked a common stock purchase agreement with White Lion Capital that will provide up to $75 million to its combination target Ocean Biomedical. Following close, Ocean may direct White Lion to purchase shares in the company worth up to $2 million or 67% of the five-day average daily trading volume. White Lion previously signed an ...
-
Synergy Biomedical Announces Publication of Core Scientific Study on Its BioSphere® Bone Graft Technology
Synergy Biomedical, LLC, a developer of innovative bone graft products for spine and orthopedic surgery, announced the publication of a basic science study describing the findings and scientific strategies of controlling the bone formation response of bioactive glass. This study was conducted by Synergy’s founder, Mark Borden Ph.D. and a team of clinical and basic science collaborators, and ...
-
Synergy Biomedical Launches BIOSPHERE® MIS II, Next Generation Minimally Invasive Bone Graft Delivery System
Synergy Biomedical, LLC, a developer of innovative biomaterial products, today announced the launching of BIOSPHERE® MIS II, Next Generation Minimally Invasive Bone Graft Delivery System. Synergy continues to add solutions for surgeons with new innovative biomaterial products to an already successful portfolio. Leveraging off the proven success of the first-generation design, BIOSPHERE® ...
-
Enalare Therapeutics Invited to Present at BARDA Industry Day 2021
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has been invited to present at the BARDA Industry Day being held virtually Nov. 3-4, 2021. The Biomedical Advanced Research and Development Authority (BARDA) is a component of the Office of the Assistant ...
-
Synergy Biomedical Announces FDA Clearance of BIOSPHERE FLEX
Synergy Biomedical, LLC, a developer of innovative biomaterial products, announced today that it has received FDA 510(k) clearance of BIOSPHERE® FLEX and is targeting a launch in the 4th quarter of 2018. Based on Synergy’s BioSphere® Technology, BIOSPHERE® FLEX is composed of porous, bioactive glass granules combined with a porous collagen and sodium hyaluronate scaffold. The ...
-
ABK Biomedical partners with the CNIC to enhance patient care
ABK Biomedical, which is developing a transformative Eye90 microspheres® technology, with the potential to provide in-procedure prognostic dosimetry for cutting-edge treatment of liver tumours – has partnered with the Canadian Nuclear Isotope Council. The CNIC is an independent body made up of representatives from the Canadian health sector, nuclear industry and leading research ...
-
Synergy Biomedical Launches BIOSPHERE® Flex SP Extremities, Synthetic Bioactive Bone Graft.
Synergy Biomedical, LLC, a developer of innovative biomaterial products, today announced the launching of BIOSPHERE® FLEX SP EXTREMITIES, Synthetic Bioactive Bone Graft. Using Synergy’s proprietary BIOSPHERE® Technology, BIOSPHERE® FLEX SP Extremities is a sheet putty composed of innovative spherical bioactive glass granules combined with a porous collagen/sodium hyaluronate ...
-
Vitanova Biomedical and LiteCure Medical Lasers Announce Global Strategic Partnership
Vitanova Biomedical, the San Antonio, Texas-based biotechnology company dedicated to improving the lives of cancer patients and the healthcare professionals who care for them, has entered a global strategic partnership with LiteCure Medical Lasers. Vitanova’s light-activated targeted cancer drug offers a cost effective and efficacious cancer therapy with the potential to eliminate unwanted ...
-
CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs
The combination of real-life data sets in rare diseases with innovative big data/artificial intelligence/novel scientific computational knowledge will transform biomedical research, product development, and therapy. Real-life data and Innovative Bioinformatic Algorithms (RIBA project) will enable the creation of a powerful environment to accelerate, de-risk, and improve the development of new ...
-
Celdara Medical Announces Funding for Alzheimer’s-Focused Fellowship Opportunities
Celdara Medical, LLC today announced that the National Institute of Aging’s Research and Entrepreneurial Development Immersion (REDI) initiative has awarded an R25 Entrepreneurship Enhancement Award to fund the company’s comprehensive training program focused on Alzheimer’s Disease: the Alzheimer’s-focused Celdara Medical High-Potential Entrepreneurs’ Fellowship ...
-
Bened Biomedical Completes $10M Series A, Set for Expansion into US Healthcare Market
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
-
Cytovale Secures Additional BARDA Funding for 10-Minute IntelliSep Test for Sepsis
Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, has received additional funding from Biomedical Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep sepsis risk stratification test towards commercial launch. This latest contract action, ...
-
RIVANNA Purchases New Facility Signaling Rapid Growth
RIVANNA, developers of world-first, imaging-based medical solutions, today announced the purchase of a 10,000 square-foot facility in Charlottesville, Virginia, with acreage earmarked for new construction. The venture accommodates RIVANNA’s plans to hire additional personnel and expand manufacturing capacity for its Accuro® product line, thus signaling a new growth phase for the ...
-
Visby Medical Executes Contract Option with BARDA for $25.5M to Develop Rapid Flu-COVID PCR Test Designed for At-Home Use
Visby Medical™, a leading medical diagnostic company, today announced that it has received an additional $25.5M in federal funding to develop and validate an at-home combination Flu-Covid test from the Biomedical Advanced Research and Development Authority (BARDA).The developmental-stage Flu-COVID PCR Test is a single-use, handheld, all-in-one PCR device that detects and distinguishes ...
-
Enalare Files Additional Patent Application for Lead Compound ENA-001 - Enhancing Potential Global Exclusivity Through 2042
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has filed a Provisional Patent Application with the United States Patent and Trademark Office directed to parenteral formulations of ENA-001 and related compounds. The patent application encompasses the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you